This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Görander, S.
Right arrow Articles by Liljeqvist, J.-A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Görander, S.
Right arrow Articles by Liljeqvist, J.-A.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, April 2008, p. 675-680, Vol. 15, No. 4
1071-412X/08/$08.00+0     doi:10.1128/CVI.00260-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Seroprevalences of Herpes Simplex Virus Type 2, Five Oncogenic Human Papillomaviruses, and Chlamydia trachomatis in Katowice, Poland{triangledown}

Staffan Görander,1* Teresa Lagergård,2 Malgorzata Romanik,3 Raphael P. Viscidi,4 Gayane Martirosian,3 and Jan-Åke Liljeqvist1

Departments of Virology,1 Medical Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, Göteborg University, S-413 46 Göteborg, Sweden,2 Department of Medical Microbiology, Medical University of Silesia, Katowice, Poland,3 Johns Hopkins University School of Medicine, Baltimore, Maryland4

Received 26 June 2007/ Returned for modification 31 October 2007/ Accepted 7 February 2008

Herpes simplex virus type 2 (HSV-2), human papillomaviruses (HPVs), and Chlamydia trachomatis are the most common pathogens causing sexually transmitted infections (STIs). There is limited information about the prevalences of these STIs in Poland. Here, we estimated the occurrence of immunoglobulin G (IgG) antibodies against HSV-2, HPV, and C. trachomatis in 199 blood donors and 110 patients of both genders attending an STI clinic in Katowice in southern Poland. The seroprevalences of HSV-2 were 5% for blood donors and 14% in the STI cohort. The seroprevalences of the five potentially oncogenic HPV types 16, 18, 31, 35, and 51 were 15%, 7%, 5%, 5%, and 17%, respectively, in blood donors and 37%, 8%, 12%, 5%, and 21%, respectively, in the STI cohort. The majority of HPV-infected individuals showed antibodies against more than one type, i.e., had been infected with multiple HPV types. Anti-C. trachomatis IgG antibodies were detected in 6% of blood donors and 13% of individuals attending the STI clinic. The relatively high prevalence of HPV-51 may have implications for future vaccine programs, as the newly introduced HPV vaccines are based on the potentially oncogenic HPV types 16 and 18.

* Corresponding author. Mailing address: Institute of Biomedicine, Department of Clinical Virology, University of Göteborg, Guldhedsgatan 10B, S-413 46 Göteborg, Sweden. Phone: (46) 31 3424615. Fax: (46) 31 3424960. E-mail: staffan.gorander{at}gu.se

{triangledown} Published ahead of print on 20 February 2008.

Clinical and Vaccine Immunology, April 2008, p. 675-680, Vol. 15, No. 4
1071-412X/08/$08.00+0     doi:10.1128/CVI.00260-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»